In this section

Filter by year:

Events


Newsletters

Get in contact with us








Back

News & events


  • Doris Hafenbradl joins BioFocus as Senior Director, Biology and Natural Products


    Thu 10 Dec 2009
    BioFocus, a leading provider of gene-to-drug candidate discovery services, today announced that Dr. Doris Hafenbradl has joined BioFocus as Senior Director, Biology and Natural Products, based in Basel, Switzerland.

  • BioFocus and DiscoveRx announce a co-marketing agreement for GPCR screening


    Thu 08 Oct 2009
    BioFocus® and DiscoveRx corp. announced today that they have signed a co-marketing agreement that allows BioFocus to perform screening on behalf of BioFocus’ customers using DiscoveRx PathHunter™ ß-Arrestin GPCR screening assay, HitHunter™ cAMP assays and associated cell lines.

  • BioFocus launches www.SilenceSelect.com microsite


    Fri 02 Oct 2009
    BioFocus has recently launched its new microsite, www.SilenceSelect.com, dedicated to the SilenceSelect® and FLeXSelect® adenoviral technology. With the ability to knock-down or knock-in human genes in primary cells, these collections cover most of the druggable genome. Detailed information on both collections is available on the microsite, along with details of the adenovirus technology employed.

  • BioFocus DPI announces expanded drug discovery collaboration with Schering-Plough


    Thu 24 Sep 2009
    BioFocus DPI announced today that it has initiated a drug discovery collaboration with Schering-Plough Research Institute (SPRI). Under the terms of the agreement, BioFocus DPI will perform medicinal chemistry with supporting biology and ADME/PK services for multiple Schering-Plough drug discovery projects. Total contract value for BioFocus DPI is €2.8 M over a one year period.

  • BioFocus DPI launches compound library targeting protein-protein interactions plus three new kinase libraries


    Mon 21 Sep 2009
    BioFocus DPI, a leading provider of gene-to-drug candidate discovery services, today announced the launch of four new biologically targeted libraries. These new libraries contain novel, drug-like compounds that specifically target kinases and - for the first time - protein-protein interactions.



  • BioFocus DPI and Procter & Gamble sign compound management agreement


    Wed 12 Aug 2009
    BioFocus DPI announced today that it has signed a three year compound management agreement with Procter & Gamble Co. (P&G). Under the agreement, BioFocus DPI will manage P&G’s chemical library collection. These services will be provided by BioFocus DPI’s compound management facility in South San Francisco, USA.

  • BioFocus DPI and Oncodesign forge alliance to provide integrated oncology drug discovery services


    Mon 27 Jul 2009
    BioFocus DPI and Oncodesign announced today that they have joined forces to offer a comprehensive oncology drug discovery service. The alliance combines BioFocus DPI’s target discovery and screening capabilities with Oncodesign’s experimental pharmacological and biomarker expertise in oncology. In addition, the partners will contribute their complementary medicinal chemistry expertise to form a drug discovery service specialized in the rapid generation of promising anticancer drug candidates.

  • Dates announced for free GPCR conference


    ‘Novel Applications and Cutting Edge Technologies for GPCR Screening and Profiling’
    Thu 09 Jul 2009
    Saffron Walden, UK; 8 July 2009 - Taking place at The Nucleus conference centre, Chesterford Research Park, Saffron Walden, UK from 22 - 23 September 2009, the new scientific conference ‘Novel Applications and Cutting Edge Technologies for GPCR Screening and Profiling’ will provide delegates with the opportunity to hear from thought leaders and share experiences within this rapidly developing field.

  • Institute for OneWorld Health Announces Successful Collaboration to Fight Neglected Diarrheal Diseases in Developing Countries


    Screening of Roche Proprietary Compound Library Yields Promising Results
    Mon 18 May 2009
    The Institute for OneWorld Health, the US-based non-profit pharmaceutical company that develops drugs for people with neglected infectious diseases in the developing world, today announced that it has successfully completed its first screening campaign of the Roche proprietary compound library and will select up to 40 new drug leads for further study intended to identify a new treatment for childhood diarrhea.

  • BioFocus DPI launches six new SoftFocus libraries


    Mon 27 Apr 2009
    BioFocus DPI, a leading provider of gene-to-drug candidate discovery services, today announced the launch of six new biologically targeted libraries.

  • BioFocus DPI to apply TET Technology in high-throughput screening campaigns


    Fri 24 Apr 2009
    BioFocus DPI and TET Systems Holding announced today that they have entered into an agreement to apply TET System's inducible gene technology in high-throughput screening campaigns performed for BioFocus DPI customers.

  • BioFocus DPI enhances high-throughput screening library


    Thu 23 Apr 2009
    BioFocus DPI announces that it has added 350,000 new compounds to its diverse screening library.

  • BioFocus DPI and Medicines for Malaria Venture collaborate to identify anti-malarial compounds


    Thu 16 Apr 2009
    BioFocus DPI, a leading provider of gene-to-drug candidate discovery services, and the not-for-profit organization Medicines for Malaria Venture (MMV) announce the start of a collaboration to identify new natural product and small molecules that demonstrate anti-malarial activity.

  • Royal Approval for Chesterford Research Park


    Fri 03 Apr 2009
    His Royal Highness the Duke of York visited Chesterford Research Park today to tour the site and meet with senior management from R&D companies based at the Park.

  • BioFocus DPI enhances ADME/PK Laboratory bioanalytical capabilities


    Thu 26 Feb 2009
    BioFocus DPI announces that it has strengthened its ADME/PK Laboratory bioanalytical capabilities through the installation of a Waters® Xevo™ TQ Mass Spectrometer.

  • BioFocus DPI extends drug discovery collaboration with Lilly


    Tue 24 Feb 2009
    BioFocus DPI, the service division of Galapagos, has extended its drug discovery agreement with Eli Lilly and Company until end 2009. Under the terms of the agreement, BioFocus DPI will identify active compounds by screening of Lilly’s library compounds.

  • BioFocus DPI enhances high-content screening capabilities


    Mon 05 Jan 2009
    BioFocus DPI has significantly enhanced its high-content screening capabilities through the implementation of precision liquid handling instruments and advanced cell imaging devices.



Bookmark with:

What are these?


Print to HTML Print as PDF Send to a friend



BioFocus®, SoftFocus®, Galapagos®, SilenceSelect® and FLeXSelect® ThemePair™, FieldFocus™, HDRA™. Helical Domain Recognition Analysis™, 2D Roadmap™, Thematic Analysis™, SFK™, SFI™, SFG™ and PrimePath™ are trademarks of Galapagos NV and/or its affiliates.